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Antineutrophil cytoplasmic antibodies and associated diseases: ternational Consensus Statement on Testing and Re-
A review of the clinical and laboratory features. There have porting of ANCA” has been developed to optimize the
been a number of recent advances in this field. First, the “Inter- usefulness of ANCA testing and to ensure more unifor-national Consensus Statement on Testing and Reporting of
mity in the laboratory results that are issued. It requiresAntineutrophil Cytoplasmic Antibodies (ANCA)” has been de-
veloped to optimize ANCA testing. It requires that all sera that all sera should at least be tested by indirect immu-
are tested by indirect immunofluorescent (IIF) examination of nofluorescent (IIF) examination of normal peripheral
normal peripheral blood neutrophils and, where there is posi- blood neutrophils and, where there is positive fluo-
tive fluorescence, in enzyme-linked immunosorbent assays
rescence, in enzyme-linked immunosorbent assays(ELISAs) for antibodies against both proteinase 3 (PR3) and
(ELISAs) for antibodies against proteinase 3 (PR3) andmyeloperoxidase (MPO). Testing will be further improved
when international standards and common ELISA units are myeloperoxidase (MPO). Testing could be further im-
available. Second, new diagnostic criteria for the small vessel proved by the development of international standards
vasculitides that take into account ANCA-positivity and target
and the adoption of common ELISA units. Current diag-antigen specificity as well as histologic features are currently
nostic criteria for the small vessel vasculitides do not takebeing produced. Third, we understand that the complications
associated with treatment of the ANCA-associated vasculitides account of ANCA positivity or target antigen specificity,
are often more hazardous than the underlying disease, and despite correlations with patterns of organ involvement
regimens that use effective but less toxic agents are being and with the tendency to relapse. New criteria that in-evaluated. The factors associated with increased risk of relapse,
clude these features are now being developed by thehowever, remain incompletely understood. Finally, ANCA
with specificities other than PR3 and MPO are present in many Chapel Hill group. “Overlap syndromes” in which there
nonvasculitic autoimmune diseases. Their clinical significance is medium, as well as small vessel involvement, are recog-
is still largely unclear, and some of the target antigens are nized with increasing frequency. We have come to under-
present in other cells as well as neutrophils and thus are not
stand that the ANCA-associated vasculitides are not in-strictly “ANCA.”
variably fatal when treated appropriately and that the
complications associated with relapses, especially in the
older population, can be less hazardous than the therapy.The association of antineutrophil cytoplasmic antibod-
Thus, regimens that use effective but less toxic agentsies (ANCA) with the small vessel vasculitides has proved
are being actively sought. The risk factors for relapseshelpful in the diagnosis and management of Wegener’s
in the ANCA-associated vasculitides and for the devel-granulomatosis, microscopic polyangiitis, and Churg–
opment of generalized disease in Wegener’s granuloma-Strauss syndrome, but the lack of technical guidelines
tosis are incompletely understood at the present time.for antibody testing had meant that it was often difficult
ANCA with specificities other than PR3 and MPO areto compare results from different laboratories. The “In-
frequently demonstrated in patients with inflammatory
bowel disease, autoimmune liver disease, rheumatoid
Key words: ANCA, crescentic glomerulonephritis, microscopic polyan-
arthritis, and some drug-induced vasculitides. In thesegiitis, pauciimmune segmental necrotizing glomerulonephritis, small
vessel vasculitis, Wegener’s granulomatosis. conditions, ANCA often have multiple specificities, and
antibody levels are usually low. Some of these antigens
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are present in cells other than neutrophils and are thusand in revised form July 13, 1999
Accepted for publication July 21, 1999 not strictly “ANCA.” The clinical significance of many of
these antibodies is still unclear. There have been severalÓ 2000 by the International Society of Nephrology
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Table 1. Summary of the International Consensus Statement onexcellent reviews of the clinical and pathologic aspects
Testing and Reporting of ANCA
of ANCA-associated vasculitides [1–6], but this article
Testingemphasizes recent developments from the ANCA Work-
Minimum requirements
shops. • IIF is performed on all sera, since about 10% of ANCA-positive
sera are detected only by IIF
• Sera containing ANCA, any other cytoplasmic fluorescence, or
an ANA that results in homogeneous or peripheral nuclearDIAGNOSIS OF SYSTEMIC SMALL
fluorescence should be tested promptly in ELISAs for bothVESSEL VASCULITIDES
PR3- and MPO-ANCA
• Sera from patients that were previously ANCA-positive by IIFThe ANCA-associated small vessel vasculitides in-
alone may be tested subsequently only by IIFclude Wegener’s granulomatosis, microscopic polyan-
• Sera that were positive for either PR3- or MPO-ANCA may
giitis, renal-limited microscopic polyangiitis, Churg– be tested subsequently only in the relevant ELISA (although
ANCA sometimes change antigen specificity)Strauss syndrome, and some drug-induced vasculitides
[7–12]. The term “polyangiitis” is preferred to “polyarte- Optimal recommendations
• IIF titration should be performed for sera positive only by IIF,ritis” because vessels of various sizes are affected and
or if other cytoplasmic fluorescence, or an ANA is presentarteries are often not involved. In patients with primary
• ELISAs should be performed on all sera since about 5% of
pauciimmune crescentic glomerulonephritis, the pres- ANCA-positive sera are positive only by ELISA
• The inclusion of the most recent positive serum in the IIF orence of a necrotizing glomerular lesion, the demonstra-
ELISA studies may be useful in demonstrating a change intion of ANCA, and the response to immunosuppressive
antibody level
agents suggested that this was a renal-limited form of
Reportingmicroscopic polyangiitis, even though patients often
Nomenclature
have constitutional symptoms [13]. • Reports should use the terms “C-ANCA” for cytoplasmic fluo-
rescence with interlobular accentuation; “C-ANCA (atypical)”Wegener’s granulomatosis, microscopic polyangiitis,
for other types of cytoplasmic fluorescence; “P-ANCA” forand Churg–Strauss syndrome are relatively uncommon
perinuclear or granulocyte-specific nuclear fluorescence; and
conditions but are being diagnosed with increasing fre- “atypical ANCA” for other, less common patterns, such as
mixed cytoplasmic and perinuclear fluorescencequency, in part because of the widespread use of ANCA
• Antigen specificities demonstrated by ELISA are described astesting [14]. However, there are currently no satisfactory
“PR3-” and “MPO-ANCA”
definitions for these diseases. The American College of
ReportsRheumatology (ACR) criteria do not recognize the diag-
• Any report of positive neutrophil fluorescence issued before
nosis of microscopic polyangiitis, and classify such pa- the ELISA results are available should indicate that positive
fluorescence alone is not specific for the diagnosis of Wegener’stients as having Wegener’s granulomatosis, Henoch-
granulomatosis or microscopic polyangiitisScho¨nlein purpura, or hypersensitivity angiitis [15, 16].
• Reports should indicate that decisions about treatment should
The Chapel Hill definitions require histologic evidence not be based solely on the ANCA results
or the presence of clinical features that indicate the un- Modified from [23] with permission from the American Journal of Clinical
Pathology. Abbreviations are in the Appendix.derlying pathology to make a diagnosis [17]. Thus, with
the Chapel Hill criteria, a patient has Wegener’s granulo-
matosis when there is necrotizing granulomatous in-
ANCA) or MPO has further implications for organflammation, often of the respiratory tract, but no history
involvement, histopathology, and the likelihood of re-of asthma, and microscopic polyangiitis when there is a
lapse [19, 20]. The Chapel Hill criteria are currentlypauciimmune small vessel vasculitis in the absence of
being revised to allow for ANCA positivity and antigengranulomatous inflammation and asthma. When the
specificity.ACR and Chapel Hill definitions are applied to a cohort
of patients with vasculitis, they identify different but
overlapping groups (abstract; Bruce et al, Sarcoidosis TESTING FOR ANTINEUTROPHIL
Vasc Diffuse Lung Dis 13:270, 1996) [18]. Neither the CYTOPLASMIC ANTIBODIES
ACR nor current Chapel Hill criteria takes into account The most common reason to request a test for ANCA
ANCA positivity and target antigen specificity, even is to diagnose or exclude Wegener’s granulomatosis or
though these are probably important clues to the nature microscopic polyangiitis and to monitor inflammatory
of the underlying vasculitis and to subsequent disease activity in these diseases. Recent retrospective and pro-
behavior. For example, the demonstration of ANCA will spective studies have suggested that the results of ANCA
indicate an ANCA-associated vasculitis when there is testing have a low sensitivity and specificity for at least
only glomerular sclerosis or tubulointerstitial disease, Wegener’s granulomatosis [21, 22], but these analyses
and when the histologic appearance cannot be distin- have used the ACR criteria for diagnosis and have dem-
guished from that seen with Henoch Scho¨nlein purpura, onstrated ANCA by neutrophil IIF alone.
cryoglobulinemia, and serum sickness. The subsequent The “International Consensus Statement on Testing
and Reporting of ANCA” (Table 1) has been developeddemonstration of specificity for proteinase 3 (PR3-
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Table 2. Clinical indications for ANCA testing accentuation accounts for half of all cytoplasmic fluores-
• Glomerulonephritis, especially rapidly progressive glomerulonephritis cence in some laboratories [29]. These sera rarely have
• Pulmonary hemorrhage, especially pulmonary–renal syndrome PR3 specificity and recognize such antigens as bacteri-
• Cutaneous vasculitis, especially with systemic features
cidal/permeability-increasing protein (BPI), MPO, and• Multiple lung nodules
• Chronic destructive disease of the upper airways so forth [31]. Cytoplasmic fluorescence is also seen with
• Long-standing sinusitis or otitis heat-treated sera, with antimitochondrial and antiribo-
• Subglottic tracheal stenosis
somal antibodies, and with some alloantibodies [31–33].• Mononeuritis multiplex or peripheral neuropathy
• Retro-orbital mass Perinuclear fluorescence without the nuclear extension
characteristic of MPO specificity [32] can still occur withThe presence of any of these features in the absence of another obvious cause
indicates that ANCA testing is warranted. Modified from [24] with permission MPO-ANCA, but is common in inflammatory bowel
from Nephrology.
disease and rheumatoid arthritis [34, 35]. Granulocyte-
specific ANA represent a form of P-ANCA, and the
International Consensus Statement recommends that
to optimize the diagnostic usefulness of ANCA testing they are described as such. The corresponding antigen
in patients suspected of having vasculitis, by the adoption specificities are unclear. P-ANCA should be distin-
of standardized testing and reporting procedures [23]. guished from the fluorescence seen with anti-dsDNA,
Table 2 shows the clinical manifestations that suggest the anti-Ro, anti-lamin, and anti-Golgi antibodies [31].
diagnoses of Wegener’s granulomatosis and microscopic “Atypical” ANCA patterns are uncommon and often
polyangiitis [24], and indicate that a test for ANCA comprise a mix of cytoplasmic and perinuclear fluores-
should be performed. In such patients, ANCA positivity cence with multiple antigen specificities [23]. They occur
is more likely to indicate a vasculitis than in other hospi- with propylthiouracil and other drugs, even if there is no
tal patients. The International Consensus Statement has vasculitis, and are also observed in inflammatory bowel
adopted the recommendation of the European standard- disease and rheumatoid arthritis.
ization trials that ANCA testing for the diagnosis of In contrast to IIF, ELISAs for PR3- and MPO-ANCA
vasculitis requires both IIF examination of normal pe- produce an immediate estimate of antibody levels, which
ripheral blood neutrophils and ELISAs for PR3- and
are usually high at the time of presentation with general-MPO-ANCA [25]. When the IIF assay is positive and
ized Wegener’s granulomatosis or microscopic polyangi-one ELISA is performed depending on the IIF pattern,
itis and which fall with treatment [36]. The inclusion ofthis approach produces sensitivities of 73 and 67% for
a recent serum in the IIF assay or ELISA may demon-Wegener’s granulomatosis and microscopic polyangiitis,
strate a change in antibody level that helps with patientrespectively, and a diagnostic specificity of 99% [26]. A
management. The sensitivity of ANCA ELISAs is in-similar approach yields positive and negative predictive
creased with the “capture” methodology [37], where thevalues of 95 and 85% for Wegener’s granulomatosis and
target antigens are bound to specific monoclonal anti-microscopic polyangiitis, respectively, when there is kid-
bodies adherent to the plastic ELISA plates, thus over-ney involvement [27]. These values should be increased
coming the effect of protein denaturation from extrac-by adhering to the minimum requirements of the Inter-
tion or coating procedures. The results with capturenational Consensus Statement, where both ELISAs are
ELISAs probably correlate better with disease activityperformed when the IIF is positive, or the optimal recom-
and predict relapses more accurately than conventionalmendations that all sera should be tested by IIF and in
assays. Rapid-screening ELISAs, in which results areboth ELISAs.
available in less than 60 minutes, and “near patient”Four patterns are demonstrated with IIF (Fig. 1).
testing assays that use whole blood are also available.Probably 90% of patients with active generalized Weg-
Most laboratories use commercial kits for both IIFener’s granulomatosis have granular cytoplasmic neutro-
and ELISAs, and there is good concordance betweenphil fluorescence with central interlobular accentuation
IIF positivity using different types of neutrophil prepara-(“C-ANCA”) that usually corresponds to PR3 specificity
tions, although the fluorescent patterns may differ. How-[28]. About 80% of patients with microscopic polyangi-
ever, sera with C-ANCA produced a concordance rateitis or Churg–Strauss syndrome are ANCA positive, and
of 56% with seven different PR3-ANCA kits and seramost with microscopic polyangiitis and about half with
with P-ANCA, a rate of only 30% using eight differentChurg–Strauss syndrome have perinuclear neutrophil
MPO-ANCA assays [38]. Additionally, while PR3-staining, often with nuclear extension (“P-ANCA”) and
ANCA levels correlated with C-ANCA intensity, thereMPO specificity [10], while the rest have C-ANCA.
was no such correlation between MPO-ANCA andHowever, most neutrophil fluorescence detected in
P-ANCA levels. Further obstacles to the direct compari-a routine immunodiagnostic laboratory is not seen in
son of ELISA results from different assays are the lackpatients with Wegener’s granulomatosis or microscopic
of international serum standards and the absence of unitspolyangiitis [29, 30]. “C-ANCA (atypical)” with “flat”
neutrophil cytoplasmic fluorescence and without central for PR3- and MPO-ANCA.
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Fig. 1. Immunofluorescence patterns. (A) C-ANCA with cytoplasmic staining, central accentuation and PR3 specificity. (B) C-ANCA (atypical)
with flat cytoplasmic fluorescence and where the antigen was not PR3. (C) P-ANCA with perinuclear fluorescence and nuclear extension, where
the antigen was MPO. (D) Atypical ANCA, with both cytoplasmic and perinuclear fluorescence, and where both PR3 and MPO were recognized.
Other autoantibodies are common in patients with TARGET ANTIGENS
Wegener’s granulomatosis and especially microscopic Many of the target antigens of ANCA are located in
polyangiitis (abstract; Geffriaud et al, Clin Exp Immunol the primary granules of neutrophils and have antibacte-
93:41, 1993) [39, 40], but are not necessarily present con- rial properties (Table 3). PR3 and MPO are recognized
temporaneously with ANCA [40]. An ANA occurs in in most ANCA-positive small vessel vasculitides. PR3 is
up to 30% of patients, and these IIF patterns vary and a 29 kD serine protease that breaks down tissue to allow
may mask a P-ANCA, which is why the International the passage of neutrophils into an inflammatory focus
Consensus Statement recommends that sera containing [44] and is also involved in neutrophil maturation [45].
an ANA should be tested for both PR3- and MPO-
MPO helps generate hypochlorite molecules and reac-
ANCA. Rheumatoid factor is also common [39]. Anti-
tive oxygen species that are bactericidal [46]. In patientsglomerular basement membrane (GBM) antibodies oc-
with vasculitis affecting the kidney, ANCA specific forcur together with ANCA in about 5% of patients with
human lysosomal membrane glycoprotein (h-lamp2)vasculitis (abstract; Coulthart et al, Clin Exp Immunol
have been described together with PR3- or MPO-101:60, 1995). These are usually P-ANCA, but some-
ANCA, and may result from cross-reactivity with a renaltimes C-ANCA [41]. Anti-GBM disease can resemble
endothelial surface protein [47]. Their significance, how-Wegener’s granulomatosis and microscopic polyangiitis
ever, is unclear.clinically, and some laboratories routinely test all sera at
PR3- and MPO-ANCA occur also in a number ofpresentation for anti-GBM antibodies as well as ANCA
other nonvasculitic autoimmune diseases. Their immuno-[42]. Anticardiolipin antibodies [40] and a lupus antico-
globulin class, subclass, and epitope specificity are thoughtagulant [43] occur in possibly 20% of patients and are
to differ from vasculitis-associated ANCA [48]. Addi-associated with an increased risk of thrombosis (abstract;
tional ANCA antigens are recognized in inflammatoryMistry et al, Sarcoidosis Vasc Diffuse Lung Dis 13:270,
1996). bowel disease, autoimmune liver disease, and rheuma-
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Table 3. Disease associations of ANCA defined by immunofluorescence patterns and antigen specificities
IIF pattern Antigens Disease associations
C-ANCA PR3 alone Wegener’s granulomatosis (80–90%)
Microscopic polyangiitis (20–40%)
Primary pauciimmune crescentic glomerulonephritis (20–40%)
Churg–Strauss syndrome (35%)
C-ANCA (atypical) BPI alone Cystic fibrosis (80%)
BPI, MPO, CG, etc., often multiple Inflammatory bowel disease
Primary sclerosing cholangitis
Rheumatoid arthritis
P-ANCA MPO alone Microscopic polyangiitis (50%)
Primary pauciimmune crescentic glomerulonephritis (50%)
Churg–Strauss syndrome (35%)
Multiple specificities including: Inflammatory bowel disease
• HMG1/2 Rheumatoid arthritis
• catalase Drug-induced vasculitis
• aenolase Autoimmune liver disease
• actin
also,
• lactoferrin
• lysozyme
• elastase Drug-induced syndromes
• cathepsin G
• defensin Some parasitic infestations
Atypical ANCA Multiple specificities see above Drug-induced systemic vasculitis
Inflammatory bowel disease
Rheumatoid arthritis
Granulocyte-specific ANA is a form of P-ANCA; many laboratories do not distinguish between P-ANCA and atypical ANCA, and for this reason the frequencies
of atypical ANCA are not given. Data are from references given in the text.
toid arthritis and include catalase, a enolase, high mobil- The characteristic glomerular lesion is a focal segmen-
ity group nonhistone chromosomal proteins (HMG1 and tal necrotizing glomerulonephritis usually with crescents,
HMG2), actin, BPI, cathepsin G, elastase, lactoferrin, and sometimes with disruption of Bowman’s capsule and
and lysozyme (abstract; Flesch et al, Am J Kidney Dis periglomerular tubulointerstitial inflammation from the
18:201, 1991) [49–56]. ANCA specific for these antigens spillage of inflammatory mediators. There is less endo-
individually result in P-ANCA, except for BPI-ANCA, capillary hypercellularity and more disruption of Bow-
which sometimes produces C-ANCA (atypical) [57]. How- man’s capsule than occurs in immune complex crescentic
ever, ANCA in inflammatory bowel disease, autoim- glomerulonephritis. Uninvolved glomerular segments
mune liver disease, and rheumatoid arthritis often have are often almost normal, and tubulointerstitial disease
multiple specificities, resulting in an “atypical” fluores- sometimes occurs without any obvious glomerulone-
cence pattern. Interestingly h-lamp2, catalase, a enolase, phritis.
HMG1 and HMG2, and actin are all found in cells other Immunofluorescence microscopy of the glomeruli and
than neutrophils, and while currently described as other vessels characteristically demonstrates few immu-
“ANCA,” may be more accurately named in the future. noglobulin deposits [61], which distinguishes the lesions
Further antigens include defensins [58] that have been from immune complex glomerulonephritis where there
recognized in some parasitic infections, and azurocidin are granular deposits, and from the linear staining of anti-
[59], which is of uncertain significance. GBM disease. However, there is some overlap between
the amount of immunoglobulin seen in pauciimmune
PATHOLOGY and immune-complex–mediated glomerulonephritis, and
thus, the frequency of ANCA positivity in immune com-The characteristic histologic lesion of the ANCA-asso-
plex glomerulonephritis depends on the definition ofciated small vessel vasculitides is focal fibrinoid necrosis
“pauciimmune” [62].of the capillaries and venules. However, involvement of
Lung disease is common in the ANCA-associated smallarterioles and small arteries is common [17], and “over-
vessel vasculitides (Tables 4 and 5). Capillaritis is thelap” with medium or large vessel disease occurs in nearly
most frequently seen vascular lesion [63], and airwayshalf of all patients with microscopic polyangiitis [60]. By
and interstitial disease are more common when C-ANCAconvention, when medium or large vessel involvement
is present, but otherwise, there is no histologic lesionoccurs, the disease is still called microscopic polyangiitis,
Wegener’s granulomatosis, or Churg–Strauss syndrome. that differentiates between C-ANCA and P-ANCA–
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Table 5. Pulmonary lesions in ANCA-associated vasculitidesTable 4. Approximate frequency of organ involvement in
ANCA-associated vasculitides
P-ANCA C-ANCA Total
(N 5 14) (N 5 13) (N 5 27)Wegener’s Microscopic Churg–Strauss
Organ granulomatosis polyangiitis syndrome
Alveolar hemorrhage 11 (79%) 8 (62%) 19 (70%)
Vascular lesions 11 (79%) 10 (77%) 21 (78%)Skin 40% 40% 60%
Kidney 80% 90% 45% Capillaritis 9 (64%) 8 (62%) 17 (41%)
Airway lesions 3 (21%) 8 (62%) 11 (41%)Lungs 90% 50% 70%
Ear, nose, throat 90% 35% 50% Interstitial lesions 8 (57%) 13 (100%) 21 (78%)
Diffuse alveolar damage 9 (64%) 7 (54%) 16 (59%)Musculoskeletal 60% 60% 50%
CNS 50% 30% 70% Pleural lesions 2 (14%) 5 (38%) 7 (26%)
Gut 50% 50% 50% Modified from [63] with permission from the American Journal of Clinical
Pathology.Modified from [5] with permission from the New England Journal of Medicine.
responded to treatment [71]. Central nervous systemassociated disease. The corresponding radiographic ab-
disease is recognized increasingly with the use of mag-normalities are nodules, bilateral fluffy opacities, and
netic resonance imaging. Skin lesions usually parallel theless often lobar consolidation and honeycomb lung [64].
activity in other organs.Open lung biopsy of the pulmonary parenchyma has the
Wegener’s granulomatosis is rare in the very young.highest diagnostic yield, with characteristic abnormali-
However, in children over the age of 7 and in adolescents,ties in more than 90% of specimens [65]. Transbronchial
the features resemble adult disease, except that subglot-biopsies of tracheobronchial lesions, and even renal biop-
tic stenosis and nasal deformity are more common, andsies, are usually more helpful than transbronchial biopsies
fewer cyclophosphamide-related malignancies ensueof alveolar tissue [66]. Within a week of starting treat-
[72]. As in adults, early recognition and treatment arement, the histologic appearance of these lung abnormali-
important to improve the renal outcome [73]. Pregnancyties begins to improve, but interstitial fibrosis commonly
is uncommon in the age group affected by Wegener’sresults [67].
granulomatosis, but may trigger the onset of disease and
relapse [74]. Cyclophosphamide is teratogenic in the first
CLINICAL SYNDROMES OF ANTINEUTROPHIL trimester of pregnancy.
CYTOPLASMIC ANTIBODY-ASSOCIATED About half of all patients with Wegener’s granuloma-
VASCULITIDES tosis are aged over 60 years. In the older population,
The pattern of organ involvement is similar in Wegen- presenting features are similar to those in younger indi-
er’s granulomatosis and microscopic polyangiitis (Table viduals, but the outcome is often worse, with uncon-
4). Together these diseases account for 60% of all pa- trolled pulmonary vasculitis and treatment-associated in-
tients with rapidly progressive glomerulonephritis [68] fections being common causes of death [75, 76]. ANCA
and are the most common cause of the pulmonary–renal do not occur incidentally in the normal older population,
syndrome in adults [69]. These observations contrast unlike ANA and rheumatoid factor [77].
with Churg–Strauss syndrome, in which renal failure and
Genetic risk factors for the development ofpulmonary hemorrhage are less common.
Wegener’s granulomatosis
“Limited” Wegener’s granulomatosis Patients with Wegener’s granulomatosis or PR3-
Patients with “limited” Wegener’s granulomatosis ANCA are more likely to have abnormal a1-antitrypsin
have disease affecting the eyes, ears, nose, or lungs, but (a1AT) phenotypes than normal individuals [78–80]. Fur-
not the kidneys, and about 60% are ANCA positive [70]. thermore, patients with the Z phenotype have more or-
gans involved, more progressive disease, and a higher“Limited” Wegener’s granulomatosis is recognized with
mortality rate [79, 80]. a1AT is the major inhibitor ofincreasing frequency, but probably 80% of patients go
PR3 (abstract; van der Wiel et al, Am J Kidney Dison to develop renal involvement [1], indicating that “lim-
18:206, 1991) and competes with ANCA for binding toited” and “generalized” disease are part of a continuum
the PR3 catalytic site [81]. Thus, abnormal a1AT pheno-and that long-term follow-up is essential.
types result in high circulating concentrations of un-
“Generalized” Wegener’s granulomatosis bound uninhibited PR3 that can lead to autoantibody
production in an immunologically active environment.Patients with “generalized” Wegener’s granulomatosis
have disease affecting the kidneys as well as other organs In addition, a1AT inhibits other neutrophil proteolytic
enzymes as well as PR3, and defective or deficient a1AT(Table 4). Involvement of the nose, ear, and eye is often
overlooked, and subglottic stenosis occurs in up to 20% probably results in uninhibited enzymes and increased
tissue damage. Interestingly, however, patients with ab-of patients, often at a time when other features have
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normal phenotypes often have normal serum levels of that can be demonstrated by IIF or in antigen-specific
a1AT at presentation because the protein is an acute ELISAs. Patients with Wegener’s granulomatosis who
phase reactant. a1AT phenotyping has been recom- are ANCA negative are likely to have local disease [70].
mended in patients with Wegener’s granulomatosis or However, in one study in which only patients with gener-
PR3-ANCA–associated vasculitis to identify those at alized Wegener’s granulomatosis were examined, the 14
risk of worse disease. Other genes that may predispose ANCA-negative patients were younger, more likely to
to the development of systemic vasculitis or increased be female, and had less lung and kidney involvement, a
tissue damage in vasculitis include those corresponding lower relapse rate, and a better outcome overall than 14
to the human leukocyte antigens and the neutrophil ANCA-positive patients (abstract; Reinhold-Keller et
FcgRIIa receptor (abstract; Tse et al, Sarcoidosis Vasc al, Sarcoidosis Vasc Diffuse Lung Dis 13:267, 1996). In
Diffuse Lung Dis 13:269, 1996). contrast, in microscopic polyangiitis, there was no differ-
ence in the clinical or laboratory features or prognosisMicroscopic polyangiitis
between 22 ANCA-negative and 37 ANCA-positive pa-
Most patients with microscopic polyangiitis have glo- tients, suggesting that ANCA-negative and ANCA-posi-
merulonephritis at presentation, sometimes as their only
tive microscopic polyangiitis are the same disease (ab-clinical manifestation [82]. Pulmonary hemorrhage oc-
stract; Adu et al, Clin Exp Immunol 101:62, 1995). Onecurs in up to 40% (abstract; Mistry et al, Sarcoidosis
small study has suggested that patients with ANCA-Vasc Diffuse Lung Dis 13:269, 1996), but an association
negative microscopic polyangiitis have fewer organs af-with IgM ANCA [83] has not been confirmed. These
fected [36].patients, though, have an increased mortality rate and
about 15% subsequently develop diffuse interstitial fi- Churg–Strauss syndrome
brosis (abstract; Mistry et al, Sarcoidosis Vasc Diffuse
A review of more than 150 patients has indicated thatLung Dis 13:269, 1996).
the diagnosis of Churg–Strauss syndrome can be madeAt least half of all patients with microscopic polyangi-
when there is asthma, a peak peripheral blood eosino-itis have arterial involvement and an “overlap syndrome”
philia . 1.5 3 109/L, and a systemic vasculitis affectingwith features of both microscopic polyangiitis and poly-
two or more extrapulmonary organs [85]. These featuresarteritis nodosa [60]. Thus, in addition to glomerulone-
occur sequentially over a period of years, and the clinicalphritis, these patients may have bowel or renal ischemia
diagnosis should be confirmed histologically whereverand a peripheral neuropathy from medium vessel
involvement. Arterial disease is indicated by an arcuate possible. Myocardial vasculitis is not uncommon and is
or interlobular arteritis in the renal biopsy and the dem- a major cause of morbidity. Renal involvement is less
onstration of aneurysms at surgery or angiographically. common than in the other small vessel vasculitides.
This “overlap syndrome” differs from polyarteritis no-
dosa in that ANCA are present [60], the disease does
TREATMENTnot respond to corticosteroids alone, and relapses occur.
Treatment of generalized Wegener’s granulomatosis
Differences between proteinase 3- and and microscopic polyangiitis
myeloperoxidase-antineutrophil cytoplasmic
Histologic confirmation of the diagnosis of Wegener’santibody–associated vasculitides
granulomatosis or microscopic polyangiitis is almost al-
Patients with PR3-ANCA–associated disease have ways required before treatment is instituted because of
eye, ear, nose, and upper respiratory tract involvement the associated risks. Similar regimens are used for both
more often, as well as tissue granulomata and an in- Wegener’s granulomatosis and microscopic polyangiitis,
creased relapse rate [20, 84]. Patients with MPO-ANCA– although there have been no prospective controlled trialsassociated vasculitis are often older, usually have glomer-
in microscopic polyangiitis. The responses to treatmentulonephritis, and have other autoantibodies too [19, 84].
can be measured using “disease activity” [BirminghamWhile renal lesions are more active and kidney function
vasculitis activity score (BVAS)] [86], “disease remis-deteriorates more rapidly in patients with PR3-ANCA–
sion,” “treatment resistance,” and “relapse,” as definedassociated vasculitis [20], overall, the outcome for pa-
in Table 6 [87]. Treatment-associated morbidity oftentients and for their renal function appears to be the same
exceeds the complications from the disease or relapsefor both PR3-ANCA– and MPO-ANCA–associated dis-
[88] so that minor clinical features should probably beease [19].
tolerated rather than treated aggressively, and less toxic
Antineutrophil cytoplasmic antibody-negative regimens are being actively sought (Table 7) [89, 90].
Wegener’s granulomatosis and Most induction regimens still use oral prednisolone 1
microscopic polyangiitis mg/kg and cyclophosphamide 2 to 3 mg/kg depending
on age, renal function, and bone marrow reserve [91].About 10% of patients with Wegener’s granulomato-
sis or microscopic polyangiitis do not have ANCA This results in 75% of patients with Wegener’s granulo-
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Table 6. Criteria for treatment response in Table 7. Randomized treatment trials in the
ANCA-associated vasculitidesANCA-associated vasculitides
Early systemic disease in WG and MPA (NORAM)Remission
Stabilization or improvement of renal function (serum creatinine Any organ involvement except renal or imminent vital organ failure
• Oral corticosteroids and oral cyclophosphamideconcentration), resolution of hematuria, and resolution of extrarenal
manifestations of systemic vasculitis. Persistent proteinuria does not • Or oral corticosteroids plus weekly methotrexate
Generalized WG, MPA and renal-limited vasculitis (CYCAZAREM)indicate disease activity.
Renal disease with serum creatinine ,500 mmol/L and/or imminent
Treatment resistance vital organ failure
(A) Progressive decline in renal function with the persistence of an • Oral corticosteroids and cyclophosphamide for 3 months, and
active urinary sediment; or (B) persistence or new appearance of any continued cyclophosphamide
extrarenal manifestations of vasculitis despite immunosuppressive • Or oral corticosteroids and cyclophosphamide for 3 months, and
therapy. then azathioprine
Severe renal involvement in WG, MPA and renal-limited vasculitisRelapse
(MEPEX)Occurrence of at least one of the following: (A) rapid rise in serum
Renal disease with serum creatinine .500 mmol/Lcreatinine concentration accompanied by an active urinary sediment;
• Oral corticosteroids and cyclophosphamide and IV methylpredni-(B) a renal biopsy demonstrating active necrosis or crescent forma-
solonetion; (C) hemoptysis, pulmonary hemorrhage or new and expanding
• Oral corticosteroids and cyclophosphamide and plasma exchangenodules without evidence for infection; (D) active vasculitis of the
Refractory disease in WG, MPA (SOLUTION)respiratory or gastrointestinal tract as demonstrated by endoscopy
Frequently relapsing or progressive disease, life-threatening, stan-with biopsy; (E) iritis or uveitis; (F) new neuropathy; or (G) necrotiz-
dard treatment of no useing vasculitis identified by biopsy in any tissue.
• ATG daily for 10 subsequent days
Modified from [87] with permission from the Journal of the American Society methylprednisolone and azathioprine as necessary adjuvantsof Nephrology.
Generalized or severe renal disease in WG, MPA, renal-limited vascu-
litis (CYCLOPS)
New disease, serum creatinine .150 mmol/L
• Oral corticosteroids and cyclophosphamide and switch to azathio-
prinematosis achieving remission and 91% improving signifi-
• Oral corticosteroids and continue cyclophosphamide
cantly. Prednisolone alone is ineffective [91]. In patients • Oral corticosteroids and intermittent pulse cyclophosphamide
Early systemic or generalized WG (MUPIBAC)with rapidly progressive glomerulonephritis, pulse meth-
GFR .50 mL/min and in remission 18 months after start of anotherylprednisolone of 7 to 15 mg/kg daily for three days
clinical trial
results in the recovery of renal function even in those • No treatment
• Or mupirocin nasal ointment one week a monthwho are dialysis dependent [91–95], and while the re-
Generalized or severe renal WG, MPA or renal-limited vasculitissponse to plasma exchange is equivalent to this dose, it
(REMAIN)
is usually short lived [95–98]. Both pulse prednisolone GFR ,50 mL/min for WG only, and in remission after 18 months
from start of clinical trialand plasma exchange appear, however, to be effective
• Withdraw oral corticosteroids and azathioprine between 18 andin the treatment of pulmonary hemorrhage [95]. Pulse
24 months
cyclophosphamide probably has no advantage over con- • Or continue low dose oral corticosteroids and azathioprine until
48 monthstinuous oral administration in the induction phase of
Abbreviations are: WG, Wegener’s granulomatosis; MPA, microscopic poly-aggressive disease.
angiitis. Modified from [90] with permission from Clinical and ExperimentalMost patients respond immediately to treatment. Immunology.
Within a week, symptoms and signs improve, although
deafness and neuropathy respond more slowly and some-
times incompletely. Urinary red blood cell counts and
Relapses are more common with the shorter course ofC-reactive protein (CRP) plateau in the first week and
cyclophosphamide, but the overall loss of function andthen fall, but take up to two months to become normal.
treatment-related morbidity may be acceptable.Serum creatinine usually plateaus in the first week and
In patients with Wegener’s granulomatosis, the addi-then falls, and the maximal improvement in creatinine
tion of one double-strength tablet of trimethoprim/sulfa-clearance occurs within two months. Lung hemorrhage
methoxazole twice daily in addition to immunosuppres-often clears radiographically within a week, but nodules
sive medication reduces the frequency of upper res-take a month or more. Although ANCA are reported
piratory tract relapses [100], possibly by eradicating localto disappear within three months [99], in our experience,
S. aureus. However, it is poorly tolerated, and mupiro-it is often longer.
mycin may be preferable, although its efficacy in pre-
Maintaining remission venting relapses is still unproved.
Monthly pulse cyclophosphamide results in a lowerPrednisolone is usually tapered to 20 mg at three
cumulative dose and lower toxicity compared with dailymonths and is then reduced further. Cyclophosphamide
administration, but there are fewer disease remissions,is continued for at least a year after remission with the
a lower rate of recovery from dialysis, and more relapsesNIH regimen [91], but is replaced with azathioprine after
three to six months with the Hammersmith protocol [96]. and deaths [101]. Patients who fail to respond to monthly
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pulse cyclophosphamide can still respond to daily oral for a median of two years. Seventy-one percent achieved
remission within a median of four months, and theretreatment [102]. Pulse cyclophosphamide may be effec-
tive when given more frequently or in combination with was symptomatic improvement in an additional 12%.
However, 36% of the patients who achieved remissionpulse prednisolone [103], but weekly low-dose cyclo-
phosphamide is also associated with a high relapse rate relapsed after a median of 29 months, when the metho-
trexate dose was reduced to less than 15 mg/week. Fur-[104].
thermore, some patients with limited disease who were
Refractory disease treated with methotrexate developed renal disease [115].
There are case reports in which patients with limitedFewer than 10% patients cannot tolerate cyclophos-
phamide or fail to respond to treatment. In such cases, Wegener’s granulomatosis have responded to treatment
with trimethoprim/sulfamethoxazole [116], but none ofpulse prednisolone, plasma exchange, intravenous im-
munoglobulin (IVIg), antithymocyte globulin (ATG), eight patients treated with one double-strength tablet
twice daily in addition to an unchanged dose of immuno-and humanized monoclonal anti-CD4 and anti-CD52 an-
tibodies have been used [105–110]. suppressives achieved remission, while 3 (37.5%) im-
proved for 4, 17, or 24 months, and 5 (62.5%) progressedInitial uncontrolled reports of treatment with IVIg
and immunosuppressives were promising, but subse- [91, 111]. Any clinical improvement may have resulted
from the continued use of immunosuppressives or treat-quent studies from the same group have shown that
complete remission is rare, that renal function does not ment of intercurrent infections. In a further study [117],
trimethoprim/sulfamethoxazole alone induced a com-improve, and that the relapse rate is high [105–107]. In
addition, the treatment is expensive, and the response plete or partial remission lasting a median of 43 months
in 11 out of 19 patients (58%) with early or limitedmay be batch dependent.
Anti–T-cell treatment has a role in occasional patients Wegener’s granulomatosis, but three of the nonrespond-
ers (16%) developed severe generalized disease. Thus,[108–110]. A single course of anti–T-cell therapy in which
immunosuppressives were continued resulted in an im- trimethoprim/sulfamethoxazole alone cannot be used to
induce remission even in patients with limited disease.provement in four of five patients with a high cumulative
dose of cyclophosphamide or refractory disease [108],
Future treatmentsand partial or complete remission was maintained for
the 5 to 12 months of review. Side effects were transient, Novel treatments have been identified from our in-
creased understanding of the pathogenetic mechanismsbut repeated dosing was limited by an antiglobulin re-
sponse. In a subsequent study, all six patients with unre- underlying the ANCA-associated vasculitides [118]. These
variously reduce circulating ANCA levels, deplete neu-sponsive disease who were treated with anti-CD52 1/2
anti-CD4 antibodies [110] and in whom immunosuppres- trophils, inhibit the cytokines tumor necrosis factor-a
and interleukin-1 (such as thalidomide, oxypentifylline,sives were withdrawn improved, and while four subse-
quently relapsed after 1.5 to 18 months, these responded and soluble tumor necrosis factor receptors), inhibit the
adhesion molecules that mediate neutrophil–endotheliumto further treatment. Treatment was, however, associ-
ated with a prolonged reduction in circulating CD4 interaction (abstract; Elliott et al, Clin Exp Immunol
112:57, 1998), or interfere with T-cell responses (cyclos-counts, and some patients relapsed when counts became
normal but responded to further doses. There was no porine A [119, 120], FK506, tacrolimus, mycophenolate
mofetil [121], serolimus, and deoxyspergualin). Some ofincreased rate of opportunistic infections or lymphoma.
Treatment with anti-CD52 antibodies, nevertheless, these agents have already proved effective in individual
case reports or small prospective studies. Cyclosporineshould be reserved for patients with resistant and life-
threatening disease. (5 mg/kg/day) together with prednisolone can induce
remission even in patients with renal disease and may
Limited Wegener’s granulomatosis prevent relapses. Mycophenolate mofetil causes ANCA
levels to fall and may maintain remission. Patients with aIn patients with limited Wegener’s granulomatosis,
corticosteroids alone are still ineffective [111], but agents life-threatening disease may respond to immune ablation
and peripheral blood stem cell rescue (abstract; Bacon etless toxic than cyclophosphamide such as methotrexate
[abstract; Handrock et al, Arthritis Rheum 37:353, 1994] al, Clin Exp Immunol 112:57, 1998). However, in general,
controlled prospective studies are lacking, and clinical[112–115], trimethoprim/sulfamethoxazole [116–118], and
IVIg have been used. efficacy has been unproved.
Data support the use of weekly methotrexate in the
Treatment of Churg–Strauss syndromeinduction phase and to maintain remission in patients
with limited Wegener’s granulomatosis. In one study, Churg–Strauss syndrome is rare, and its treatment has
usually been studied in series that include patients withmore than 40 patients were treated with corticosteroids
and 20 to 25 mg methotrexate weekly, and were followed polyarteritis nodosa. In such reports, glucocorticoids
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alone and glucocorticoids together with cyclophospha- dom biopsies every one to two years. The risk of bladder
cancer is 11 times greater than for the rest of the popula-mide have been efficacious [122]. However, any patient
with organ- or life-threatening disease should probably tion after just one year of cyclophosphamide treatment
in microscopic polyangiitis [125].receive both glucocorticoids and a cytotoxic agent as the
initial treatment [122]. In contrast to the other small
Relapsesvessel vasculitides, pulse cyclophosphamide together
with steroids may be effective in the Churg–Strauss syn- The frequency of relapses depends on how they are
defined, different treatment regimens, and the durationdrome. High-dose interferon a also maintains remission
in patients who have responded incompletely to cyclo- of follow-up. With the Hammersmith regimen, 42% of
45 patients with Wegener’s granulomatosis and 27% ofphosphamide (abstract; Tatsis et al, Clin Exp Immunol
112:56, 1998). 15 with microscopic polyangiitis relapsed within a year
of presentation [36]. Relapses usually occur when the
immunosuppressive dose is reduced or ceased, especially
OUTCOME
within the first two years of treatment. Relapses are more
Morbidity in patients with Wegener’s granulomatosis common in patients with C-ANCA and PR3 specificity,
or microscopic polyangiitis results from the effects of in patients with Wegener’s granulomatosis with persis-
both the underlying disease and its treatment. It can be tent nasal S. aureus [128], and when induction treatment
quantitated using the vasculitis damage index (VDI) and does not include cyclophosphamide [91]. Relapses are
the short form 36 (SF36) [123], which measures quality equally likely in patients with limited and generalized
of life, but these tools are more useful in evaluating disease [36].
treatment protocols than in assessing individual patients. Antineutrophil cytoplasmic antibodies recur or persist
Overall, the single most important factor in determining in at least half the patients who relapse, and there is
the outcome for a patient is the presence of renal disease, usually a fourfold or greater increase in IIF titer [99],
and the strongest predictor of renal outcome is the serum and at least a doubling of IgG3 subclass ANCA [129].
creatinine at presentation [124]. The predictive value of However, relapses (and disease progression) can occur
a renal biopsy at presentation is limited, but high ANCA in the absence of ANCA positivity, and only about half of
levels or persistent circulating ANCA may be associated all patients in whom ANCA recur or who are persistently
with worse disease [125, 126]. Mortality is increased in positive will relapse.
patients who present late, who have pulmonary hemor- The average time from ANCA increase to relapse is
rhage or C-ANCA–associated disease, or who are reported to be seven weeks [36]. Most relapses involve
treated with corticosteroids alone [90, 124]. the same organs that were affected initially, but renal
Disease-related morbidity occurs in possibly 90% of involvement can occur for the first time at relapse. Lung
patients and arises from delays in instituting treatment, relapses usually occur if the lung was involved initially,
progression of subclinical disease, and the tendency to but often at new sites. Lung relapses and infections may
relapse. Complications include sinus dysfunction (in be difficult to distinguish clinically, but relapses are rare
47%), renal impairment (42%), hearing loss (35%), and in the early phase of treatment when high doses of treat-
moderate to severe respiratory disease (17%) [91]. ment are used. If confusion persists, a histologic diagnosis
The greatest risks of treatment of Wegener’s granulo- should be obtained as quickly as possible. Occasionally,
matosis with the NIH cyclophosphamide regimen are relapses affect patients on dialysis or after transplanta-
infections and bladder cancer. In one series, infections tion [36].
required hospitalization in nearly half the patients, and Minor relapses are treated with an increase in dose of
transitional cell bladder cancer was 30 times more com- corticosteroids and immunosuppressives. Major relapses
mon than in the general population [127]. Half the pa- are treated with reinstitution of the induction regimen,
tients had nonglomerular hematuria after a median of after which doses can be tapered more quickly to just
8.5 years, 70% of these had cyclophosphamide-induced above the levels at which relapse occurred. Relapses
cystitis at cystoscopy, and 16% were estimated to de- usually respond quickly to treatment and may be pre-
velop bladder cancer at 15 years. This group recom- vented by longer initial immunosuppressive courses,
mended that all patients treated with cyclophosphamide monthly ANCA monitoring [36], and long-term trimeth-
should have urine microscopy every three to six months oprim/sulfamethoxazole in patients with Wegener’s
for life. If nonglomerular hematuria was present, patients granulomatosis [100]. In one study, none of nine patients
should have a cystoscopy, and if hemorrhagic cystitis who were treated on the basis of an increase in ANCA
was demonstrated, cyclophosphamide should be ceased, subsequently relapsed, while 9 of 11 (82%) who were
except in life-threatening circumstances. Individuals with not treated did [130]. However, most clinicians would
cyclophosphamide-associated cystitis should have uri- not reinstitute or increase immunosuppressive treatment
on the basis of an increased ANCA level alone, butnary cytology every six months and cystoscopy and ran-
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Table 8. ANCA in different types of glomerulonephritis about 30% of patients with anti-GBM disease and can be
demonstrated at presentation or subsequently (abstract;ANCA
O’Donoghue et al, Am J Kidney Dis 18:208, 1991) [142–Primary pauciimmune crescentic glomerulonephritis 80–90%
AntiGBM disease 20–25% 144]. These patients have more vasculitic features, can
Immune complex crescentic glomerulonephritis 15–20% recover renal function even if initially dialysis dependent
Immune complex glomerulonephritis without crescents 5–10%
[144], and are more likely to relapse than patients withOther renal diseases ,5%
anti-GBM disease alone [142, 143]. Nevertheless, theModified from [141] with permission from the American Journal of Kidney
Diseases. prognosis is generally better than uncomplicated anti-
GBM disease, possibly because patients present earlier
with the constitutional symptoms typical of vasculitis
[144]. They usually have P-ANCA with specificity for
might observe the patient more closely and reduce drug MPO (abstract; O’Donoghue et al, Am J Kidney Dis
doses more cautiously. Many of these observations have 18:208, 1991), and anti-GBM antibody levels are often
been made in Wegener’s granulomatosis, but the princi- lower than in uncomplicated anti-GBM disease [144].
ples probably apply to microscopic polyangiitis as well There is no cross-reactivity between the GBM and MPO
[131]. antigens (abstract; O’Donoghue et al, Am J Kidney Dis
18:208, 1991), and although ANCA are more commonRenal transplantation
in all forms of crescentic glomerulonephritis, anti-GBM
Renal survival post-transplantation in patients with antibodies may occur secondary to ANCA-induced glo-
Wegener’s granulomatosis or microscopic polyangiitis is merular damage at least in some patients.
the same as for other causes of end-stage kidney disease
Drug-induced systemic vasculitis[132]. ANCA levels often fall progressively after trans-
plantation [133]. Relapses following transplantation are The most common drugs that induce ANCA and an
uncommon [134] and occur less often than in dialyzed associated vasculitis are propylthiouracil and related
patients [132]. The risk of relapse is minimized if cyclo- drugs, and hydralazine [12, 145]. ANCA can be demon-
phosphamide has been used in the induction regimen by strated at some time in about 20% of all patients treated
waiting six months after presentation or the most recent with propylthiouracil (abstract; Cohen Tervaert et al,
relapse, and preferably until ANCA are undetectable, Sarcoidosis Vasc Diffuse Lung Dis 13:280, 1996), and
and by including azathioprine and possibly cyclosporine antigen specificities are usually multiple and include
in the antirejection regimen [134–136]. Unfortunately, MPO and elastase. However, only a few patients develop
an increase in ANCA level does not necessarily precede evidence of a vasculitis, and this may appear at any time
a relapse in patients with transplants (abstract; Schmitt after treatment has begun. The vasculitis may take the
et al, Clin Exp Immunol 93:43, 1993), but those who form of purpura, arthralgia, or crescentic glomerulone-
relapse usually respond to treatment with cyclophospha- phritis. When propylthiouracil is stopped, the vasculitis
mide [137]. usually resolves quickly and ANCA levels fall, but some
patients have been treated aggressively for the glomeru-
lar lesion [146].ANTINEUTROPHIL CYTOPLASMIC
Hydralazine-induced ANCA and the associated vas-ANTIBODIES AND NONVASCULITIC DISEASES
culitis often occur after years of treatment [145]. Clinical
Antineutrophil cytoplasmic antibodies occur in a num- features and ANCA characteristics are the same as for
ber of other vasculitic and nonvasculitic diseases, and propylthiouracil-induced ANCA, but this syndrome dif-
the frequency of these conditions means that ANCA fers from hydralazine-associated lupus in that antids
positivity in a routine immunodiagnostic laboratory does DNA antibodies may be present, and there is no associa-
not necessarily indicate the diagnosis of Wegener’s gran- tion with acetylator status [145]. ANCA also occur after
ulomatosis or microscopic polyangiitis. treatment with other agents that cause a drug-induced
lupus syndrome, namely penicillamine, phenytoin, and
Other glomerulonephritides procainamide [145].
Antineutrophil cytoplasmic antibodies occur occa-
Inflammatory bowel disease and autoimmunesionally in IgA, poststreptococcal, and other forms of
liver diseaseglomerulonephritis [138–140], especially when crescents
are present (Table 8) [141], so an association with ANCA Antineutrophil cytoplasmic antibodies occur in 50 to
usually implies worse disease [139] [abstract; Bommer 70% of patients with ulcerative colitis and 20 to 40% of
et al, Nephrology 3:S794, 1997]. It is not clear whether those with Crohn’s disease [34, 49, 51, 147–151]. Fre-
ANCA contribute to or simply reflect glomerular damage. quencies vary because of different testing methodologies
and patient groups. IIF patterns are usually P-ANCAAntineutrophil cytoplasmic antibodies are present in
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or atypical ANCA. Antigens are multiple and include Lung disease
catalase, a enolase, HMG1/2, BPI, and less often cathep- Antineutrophil cytoplasmic antibodies occur in at least
sin G, lactoferrin, lysozyme, PR3, MPO and elastase, 5% of patients with interstitial lung disease, which may
and antibody levels are often low. represent the end-result of vasculitis (abstract; Gaskin
The demonstration of ANCA by IIF or antigen-spe- et al, Clin Exp Immunol 93:33, 1993). C-ANCA (atypi-
cific ELISA does not correlate with disease activity in cal) with specificity for BPI have been described in cystic
ulcerative colitis or Crohn’s disease [34, 149]. In patients fibrosis [169], and antibody levels are higher in patients
with ulcerative colitis, ANCA are independent of disease with an associated secondary vasculitis, or pseudomonas
extent, persist after colectomy, and do not predict the
colonization. C-ANCA (atypical) occur in suppurativedevelopment of pouchitis after surgery [150]. Further-
lung disease [170].more, antibody status changes with time in individual
patients [151]. In Crohn’s disease, studies that suggested
InfectionsP-ANCA occur more often when the left side of the
In addition to the associations with infections de-colon was affected [152], thus resembling the distribution
scribed earlier in this article, ANCA have been describedin ulcerative colitis, have not been reproduced [153].
in isolated cases of subacute bacterial endocarditis [171],IgA ANCA occur in both ulcerative colitis and Crohn’s
and in malaria [172], invasive amoebiasis [173], blasto-disease, but their significance is uncertain. Interestingly,
mycosis [174], leptospirosis [175], and onchocerciasisANCA have been described in patients with infective
[58]. The demonstration of ANCA in HIV [176] probablyenteritis [149].
Antineutrophil cytoplasmic antibodies occur in more results from nonspecific serum stickiness after heat treat-
than 70% of patients with primary sclerosing cholangitis ment to denature the virus, and the presence of ANCA
or chronic active hepatitis and in about 30% of patients in some of the other infections may be related in part
with primary biliary cirrhosis [154]. Again, these are to the associated hypergammaglobulinemia [30].
P-ANCA or atypical ANCA, and the specificities include
actin [53], HMG1/2 (abstract; Ozaki et al, Clin Exp Im-
munol 112:120, 1998), and the antigens recognized in CONCLUSIONS
inflammatory bowel disease. In these diseases, ANCA The demonstration of ANCA has proved enormously
may correlate with the degree of cirrhosis. ANCA are helpful in the diagnosis of the small vessel vasculitides.
uncommon in nonautoimmune liver disease [154]. While it is still not clear that ANCA actually contribute
to the pathogenesis of these diseases, there is increasingArthritis
evidence, especially from models of vascular damage,
Low levels of P-ANCA (including granulocyte-specific that this is so. However, the clinical and pathogenetic
nuclear fluorescence) or atypical ANCA have been dem-
significance of ANCA in the nonvasculitic diseases re-
onstrated in 20 to 70% patients with rheumatoid arthritis
mains poorly understood.(abstract; Braun et al, Clin Exp Immunol 93:33, 1993)
[155–160]. Multiple specificities, including HMG1/2 [53],
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APPENDIXchronic arthritis [161] and in reactive arthritis [162].
Antineutrophil cytoplasmic antibodies are described Abbreviations used in this article are: a1AT, a1-antitrypsin; ACR,
American College of Rheumatology; ANA, antineutrophil autoanti-in about 20% of patients with systemic lupus erythemato-
body; ANCA, antineutrophil cytoplasmic antibodies; ATG, antithymo-sus (SLE) and have similar patterns and specificities to
cyte globulin; BPI, bactericidal/permeability-increasing protein; BVAS,
those seen in rheumatoid arthritis [55, 163–168]. These Birmingham vasculitis activity score; C-ANCA, cytoplasmic ANCA;
ANCA probably do not correlate with particular pat- CRP, C-reactive protein; GBM, glomerular basement membrane; IIF,
indirect immunofluorescence; IL-1, interleukin-1; IVIg, intravenousterns of organ involvement [164], the presence of vasculi-
immunoglobulin; MPO, myeloperoxidase; P-ANCA, perinucleartis [165], or disease activity [166]. Individual studies have
ANCA; PR3, proteinase 3; RBC, red blood cell; SF36, short form 36
suggested that certain antigen specificities may be clini- index to measure quality of life; SLE, systemic lupus erythematosus;
TNF-a, tumor necrosis factor-a; VDI, vasculitis damage index.cally significant, but these are inconsistent [167, 168].
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